Notably, the ARCHES trial had the longest median follow-up among ARPI trials at 61.4 months. During this period, median overall survival was not reached in either treatment arm. At 5 years, 66% (two ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a New Frontiers in Prostate-Specific Membrane ...

Biomarkers reveal vital insights that could improve treatment strategies for aggressive prostate cancer, offering hope for ...

Many men with aggressive prostate cancer can experience a high rate of recurrence despite treatment. A new Phase 2 clinical ...

THOUSANDS more men should receive an existing prostate cancer drug on the NHS as research shows it could halve their death ...

The test could help direct prostate cancer patients to the best treatment option for them, researchers behind the findings ...

Exosomes transform prostate cancer care with early detection, tailored treatments, and real-time prognosis tracking for ...

Scientists say they have worked out a machine learning method with the ability to provide close to precise survival estimates ...

At the recent American Urological Association annual meeting, data on niraparib (Zejula) in treatment-naive, DNA damage ...

It's important to look carefully at the critiques prostate cancer screening guidelines and the role of PSA tests. There are ...

Prostate cancer is the most common cancer affecting American men other than skin cancer and the second leading cause of male ...

Plus: Trump’s Surgeon General nominee and MAHA; and what Israeli officials are privately saying about starvation in Gaza.